New research is increasing our understanding about why some women with the most lethal form of ovarian cancer respond much better to treatment than others.
Aditxt acquires Phexxi contraceptive gel-maker Evofem for $100m – Pharmaceutical Technology
Share this article Evofem is best known as the marketer of Phexxi vaginal gel for on-demand, hormone-free birth control. Image credit: Shutterstock/Helena Nechaeva. US-based biotech